End-stage renal disease (ESRD) patients are a population with high rates of COVID-19 and
mortality. These patients present a low response to anti-SARS-CoV-2 immunization, which is …

End-stage renal disease (ESRD) patients are a population with high rates of COVID-19 and
mortality. These patients present a low response to anti-SARS-CoV-2 immunization, which is …

Background: End-stage renal disease (ESRD) patients are a population with high rates of
COVID-19 and mortality. Fibroblast Growth Factor 23 (FGF23) is a protein hormone …

Background: 20-40% of severely ill COVID-19 patients develop acute kidney injury (AKI).
AKI is now considered to be a negative prognostic factor for survival in COVID-19 patients …

A cytokine storm drives the pathogenesis of severe COVID-19 infection and several
biomarkers have been linked to mortality. Chronic kidney disease (CKD) emerged as a risk …

Introduction: Fibroblast growth factor 23 (FGF23) belongs structurally to the endocrine FGF
protein family, which also includes FGF19 and FGF21. In the past decade, FGF23 has …

Introduction We explored the relationship and the predictive value of serum fibroblast growth
factor 21 (FGF21) with all-cause mortality, major adverse cardiovascular events (MACEs) …

Background Fibroblast growth factor 21 (FGF21) is deemed to play an important role in
kidney outcomes, while the association between FGF21 and various kidney diseases …

Background: Patients hospitalized with COVID-19 are at risk for major adverse kidney
events (MAKE). Predicting which patients will experience progression of disease and poor …

Introduction: This study was conducted to ensure the correlation between fibroblast growth
factor 23 (FGF23) and death and cardiovascular events in hemodialysis patients. Methods …